Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation

Advances in Virology

Volumn 2015, Issue , 2015, Pages

  Gantt, Soren ^a,b   Gachelet, Eliora ^a   Carlsson, Jacquelyn ^a   Barcy, Serge ^a   Casper, Corey ^a,c   Lagunoff, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84929223209     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2015/687162     Document Type: Article

References (52)

1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, "Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America," September 2014, http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultoi.pdf.
2. R. H. Gray, M. J. Wawer, R. Brookmeyer et al., "Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda," The Lancet, Vol. 357, no. 9263, pp. 1149-1153, 2001.
3. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: A Cancer Journal for Clinicians, Vol. 61, no. 2, pp. 69-90, 2011.
4. Adolescents PoAGfAa, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services, 2013.
5. N. Ford, Z. Shubber, P. Saranchuk et al., "Burden of HIV-Related cytomegalovirus retinitis in resource-limited settings: a systematic review," Clinical Infectious Diseases, Vol. 57, no. 9, pp. 1351-1361, 2013.
6. C. M. Posavad, A. Wald, S. Kuntz et al., "Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy," Journal of Infectious Diseases, Vol. 190, no. 4, pp. 693-696, 2004.
7. S. Lodi, M. Guiguet, D. Costagliola, M. Fisher, A. de Luca, and K. Porter, "Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion," Journal of the National Cancer Institute, Vol. 102, no. 11, pp. 784-792, 2010.
8. E. de Clercq, "A cutting-edge view on the current state of antiviral drug development," Medicinal Research Reviews, Vol. 33, no. 6, pp. 1249-1277, 2013.
9. S. Gantt, J. Carlsson, M. Ikoma et al., "The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro," Antimicrobial Agents and Chemotherapy, Vol. 55, no. 6, pp. 2696-2703, 2011.
10. W. A. Chow, C. Jiang, and M. Guan, "Anti-HIV drugs for cancer therapeutics: back to the future?" The Lancet Oncology, Vol. 10, no. 1, pp. 61-71, 2009.
11. S. Gantt, C. Casper, and R. F. Ambinder, "Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention," Current Opinion in Oncology, Vol. 25, no. 5, pp. 495-502, 2013.
12. T. B. Brunner, M. Geiger, G. G. Grabenbauer et al., "Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer," Journal of Clinical Oncology, Vol. 26, no. 16, pp. 2699-2706, 2008.
13. J. Buijsen, G. Lammering, R. L. H. Jansen et al., "Phase I trial of the combination of the Akt inhibitor nelfinavir and chemora-diation for locally advanced rectal cancer," Radiotherapy and Oncology, Vol. 107, no. 2, pp. 184-188, 2013.
14. R. Rengan, R. Mick, D. Pryma et al., "A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiother-apy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response," Journal of Thoracic Oncology, Vol. 7, no. 4, pp. 709-715, 2012.
15. J. Pan, M. Mott, B. Xi et al., "Phase I study of nelfinavir in liposarcoma," Cancer Chemotherapy and Pharmacology, Vol. 70, no. 6, pp. 791-799, 2012.
16. J. J. Gills, J. Lo Piccolo, and P. A. Dennis, "Nelfinavir, a new anticancer drug with pleiotropic effects and many paths to auto-phagy," Autophagy, Vol. 4, no. 1, pp. 107-109, 2008.
17. L. Xie, T. Evangelidis, and P. E. Bourne, "Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir," PLoS Computational Biology, Vol. 7, no. 4, Article ID e1002037, 2011.
18. F. Y. Liu and B. Roizman, "The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate," Journal of Virology, Vol. 65, no. 10, pp. 5149-5156, 1991.
19. M. J. Karnovsk, "A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy," Journal of Cell Biology, Vol. 27, pp. A137-A138, 1965.
20. L. E. Schnipper and C. S. Crumpacker, "Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci," Proceedings of the National Academy of Sciences of the United States of America, Vol. 77, no. 4, pp. 2270-2273, 1980.
21. J. J. Gills, J. Lo Piccolo, J. Tsurutani et al., "Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo," Clinical Cancer Research, Vol. 13, no. 17, pp. 5183-5194, 2007.
22. A. M. Petrich, V. Leshchenko, P.-Y. Kuo et al., "Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma," Clinical Cancer Research, Vol. 18, no. 9, pp. 2534-2544, 2012.
23. M. Kraus, J. Bader, H. Overkleeft, and C. Driessen, "Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance," Blood Cancer Journal, Vol. 3, no. 3, article e103, 2013.
24. M.-J. Hsu, C.-Y. Wu, H.-H. Chiang, Y.-L. Lai, and S.-L. Hung, "PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection," Virus Research, Vol. 153, no. 1, pp. 36-43, 2010.
25. N. N. Kalu, P. J. Desai, C. M. Shirley, W. Gibson, P. A. Dennis, and R. F. Ambinder, "Nelfinavir inhibits maturation and export of herpes simplex virus 1," Journal of Virology, Vol. 88, no. 10, pp. 5455-5461, 2014.
26. M. Guan, K. Fousek, and W. A. Chow, "Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer," The FEBS Journal, Vol. 279, no. 13, pp. 2399-2411, 2012.
27. E. Mahoney, K. Maddocks, J. Flynn et al., "Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anticancer therapeutics in B-cell malignancies," Leukemia & Lymphoma, Vol. 54, no. 12, pp. 2685-2692, 2013.
28. S. Thomas, N. Sharma, E. B. Golden et al., "Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors," Cancer Letters, Vol. 325, no. 1, pp. 63-71, 2012.
29. A. Brüning, P. Burger, M. Vogel et al., "Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis," Cancer Biology and Therapy, Vol. 8, no. 3, pp. 222-228, 2009.
30. D. C. Johnson and P. G. Spear, "O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus," Cell, Vol. 32, no. 3, pp. 987-997, 1983.
31. S. Chatterjee, S. Nishimuro, and R. J. Whitley, "Expression of HSV-1 glycoproteins in tunicamycin-treated monkey kidney cells," Biochemical and Biophysical Research Communications, Vol. 167, no. 3, pp. 1139-1145, 1990.
32. C. E. Isaacs, W. Xu, R. K. Pullarkat, and R. Kascsak, "Retinoic acid reduces the yield of herpes simplex virus in Vero cells and alters the N-glycosylation of viral envelope proteins," Antiviral Research, Vol. 47, no. 1, pp. 29-40, 2000.
33. M. E. Taylor and K. Drickamer, Introduction to Glycobiology, Oxford University Press, Oxford, UK, 2011.
34. A. Varki, "NCBI bookshelf," in Essentials of Glycobiology, p. 1, Cold Spring Harbor Laboratory Press, New York, NY, USA, 2nd edition, 2009.
35. N. Yamamoto, R. Yang, Y. Yoshinaka et al., "HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus," Biochemical and Biophysical Research Communications, Vol. 318, no. 3, pp. 719-725, 2004.
36. M. Federico, "HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step," Virology, Vol. 417, no. 1, pp. 37-49, 2011.
37. F. N. Linero, C. S. Sepúlveda, F. Giovannoni et al., "Host cell factors as antiviral targets in arenavirus infection," Viruses, Vol. 4, no. 9, pp. 1569-1591, 2012.
38. W. Coley, K. Kehn-Hall, R. van Duyne, and F. Kashanchi, "Novel HIV-1 therapeutics through targeting altered host cell pathways," Expert Opinion on Biological Therapy, Vol. 9, no. 11, pp. 1369-1382, 2009.
39. M. A. Khattab, "Targeting host factors: a novel rationale for the management of hepatitis C virus," World Journal of Gastroenterology, Vol. 15, no. 28, pp. 3472-3479, 2009.
40. S. A. Krumm, J. M. Ndungu, J.-J. Yoon et al., "Potent host-directed small-molecule inhibitors of myxovirus RNA-depend-ent RNA-polymerases," PLoS ONE, Vol. 6, no. 5, Article ID e20069, 2011.
41. B. Pastorino, A. Nougairède, N. Wurtz, E. Gould, and X. de Lamballerie, "Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs," Antiviral Research, Vol. 87, no. 3, pp. 281-294, 2010.
42. A. Brüning, A. Gingelmaier, K. Friese, and I. Mylonas, "New prospects for nelfinavir in non-HIV-related diseases," Current Molecular Pharmacology, Vol. 3, no. 2, pp. 91-97, 2010.
43. P. Pyrko, A. Kardosh, W. Wang, W. Xiong, A. H. Schönthal, and T. C. Chen, "HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress," Cancer Research, Vol. 67, no. 22, pp. 10920-10928, 2007.
44. L. I. Pizer, G. H. Cohen, and R. J. Eisenberg, "Effect of tuni-camycin on herpes simplex virus glycoproteins and infectious virus production," Journal of Virology, Vol. 34, no. 1, pp. 142-153, 1980.
45. E. Katz, E. Margalith, and D. Duksin, "Antiviral activity of tunicamycin on herpes simplex virus," Antimicrobial Agents and Chemotherapy, Vol. 17, no. 6, pp. 1014-1022, 1980.
46. K. G. Kousoulas, D. J. Bzik, N. Deluca, and S. Person, "The effect of ammonium chloride and tunicamycin on the glycoprotein content and infectivity of herpes simplex virus type 1," Virology, Vol. 125, no. 2, pp. 468-474, 1983.
47. G. Campadelli-Fiume, L. Poletti, F. Dall'Olio, and F. Serafini-Cessi, "Infectivity and glycoprotein processing of herpes simplex virus type 1 grown in a ricin-resistant cell line deficient in N-acetylglucosaminyl transferase I," Journal of Virology, Vol. 43, no. 3, pp. 1061-1071, 1982.
48. G. S. Taylor, J. Mautner, and C. Münz, "Autophagy in herpesvirus immune control and immune escape," Herpesviridae, Vol. 2, article 2, 2011.
49. V. le Sage and B. W. Banfield, "Dysregulation of autophagy in murine fibroblasts resistant to HSV-1 infection," PLoS ONE, Vol. 7, no. 8, Article ID e42636, 2012.
50. Y. Pei, Z.-P. Chen, H.-Q. Ju et al., "Autophagy is involved in antiviral activity of pentagalloylglucose (PGG) against Herpes simplex virus type 1 infection in vitro," Biochemical and Biophysical Research Communications, Vol. 405, no. 2, pp. 186-191, 2011.
51. D. J. Klionsky, H. Abeliovich, P. Agostinis et al., "Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes," Autophagy, Vol. 4, no. 2, pp. 151-175, 2008.
52. W. Wu, R. Zhang, and D. R. Salahub, "Nelfinavir: a magic bullet to annihilate cancer cells?" Cancer Biology and Terapy, Vol. 8, pp. 233-235, 2009.